Search - tctmd.com

Displaying 1 - 20 of 110

Sort: Relevancy | Date

Presentation ESC 2024

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Presenter: David Erlinge

September 02, 2024

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

Presentation TCT 2020

Three-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation

Presenter: Junjie Zhang

October 15, 2020

Presentation JIM 2020

The Abluminus DES+: from the technical features to the clinical program

Presenter: Luca Testa

February 13, 2020

Presentation JIM 2020

Drug-coated balloon vs. drug eluting stent for small coronary vessel disease: 6-mo. primary outcome of the PICCOLETO II randomized clinical trial.

Presenter: Bernardo Cortese

February 13, 2020

Presentation TCT Abstracts Posters 2019

Causes and predictors of 6-month readmission rate after drug eluting stent in the contemporary era- A nationwide analysis

Presenter: Syed Zaid

September 29, 2019

Presentation EuroPCR 2019

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Presenter: Clemens von Birgelen

May 21, 2019

Presentation JIM 2019

Overall Experience of Abluminus DES in Real World and Dedicate Global Clinical Registry

Presenter: Luca Testa

February 14, 2019

Presentation JIM 2019

Unmet Clinical Needs With Current Drug-Eluting Stents

Presenter: Davide Capodanno

February 14, 2019

Presentation TCT Abstracts Posters 2018

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

Presenter: Hyungdon Kook

September 25, 2018

Presentation TCT Abstracts Posters 2018

Increased Risk of Acute Stent Thrombosis Associated with Synergy® Bioabsorbable Polymer-Coated Drug-Eluting Stent after Percutaneous Coronary Intervention for Acute Coronary Syndrome

Presenter: Joel Lardizabal

September 25, 2018

Presentation EuroPCR 2018

TARGET AC A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent

Presenter: Andreas Baumbach

May 25, 2018

Presentation JIM 2018

Overview of New Generation Drug-Eluting Stents

Presenter: Gregg W. Stone

February 22, 2018

Presentation

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

February 13, 2017

Presentation JIM 2017

EluNIR™The First Elastomeric Drug Eluting Stent (eDES™)

Presenter: Alaide Chieffo

February 09, 2017

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

Presentation TCT 2016

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Giulio Guagliumi

November 02, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation ESC 2016

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Presenter: Raban V. Jeger

August 31, 2016

Presentation CCVVC 2016

Use of Drug Eluting Stents in the SFA: What are the Current Data, Real World Applications, Upcoming Trials

Presenter: Tyrone Collins

June 15, 2016

Advertisement

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Three-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation

The Abluminus DES+: from the technical features to the clinical program

Drug-coated balloon vs. drug eluting stent for small coronary vessel disease: 6-mo. primary outcome of the PICCOLETO II randomized clinical trial.

Causes and predictors of 6-month readmission rate after drug eluting stent in the contemporary era- A nationwide analysis

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Overall Experience of Abluminus DES in Real World and Dedicate Global Clinical Registry

Unmet Clinical Needs With Current Drug-Eluting Stents

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

Increased Risk of Acute Stent Thrombosis Associated with Synergy® Bioabsorbable Polymer-Coated Drug-Eluting Stent after Percutaneous Coronary Intervention for Acute Coronary Syndrome

TARGET AC A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent

Overview of New Generation Drug-Eluting Stents

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

EluNIR™The First Elastomeric Drug Eluting Stent (eDES™)

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Use of Drug Eluting Stents in the SFA: What are the Current Data, Real World Applications, Upcoming Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content